litlas
ログインアカウント作成

Yongsheng Wang

2003–2026 年に発表

358
論文数
20,030
被引用数
78
h 指数
248
i10 指数

被引用数

Yongsheng Wang の年別被引用数2005 年: 被引用 1 件2006 年: 被引用 4 件2007 年: 被引用 15 件2008 年: 被引用 21 件2009 年: 被引用 15 件2010 年: 被引用 35 件2011 年: 被引用 42 件2012 年: 被引用 55 件2013 年: 被引用 99 件2014 年: 被引用 127 件2015 年: 被引用 159 件2016 年: 被引用 181 件2017 年: 被引用 185 件2018 年: 被引用 152 件2019 年: 被引用 410 件2020 年: 被引用 602 件2021 年: 被引用 693 件2022 年: 被引用 647 件2023 年: 被引用 625 件2024 年: 被引用 1,188 件2025 年: 被引用 839 件2026 年: 被引用 42 件

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 3,020 件、この内訳の 35.9%アメリカ合衆国: 引用元論文 1,296 件、この内訳の 15.4%インド: 引用元論文 274 件、この内訳の 3.2%イギリス: 引用元論文 266 件、この内訳の 3.2%ドイツ: 引用元論文 251 件、この内訳の 3%イタリア: 引用元論文 241 件、この内訳の 2.9%フランス: 引用元論文 199 件、この内訳の 2.4%韓国: 引用元論文 189 件、この内訳の 2.2%オーストラリア: 引用元論文 188 件、この内訳の 2.2%イラン: 引用元論文 171 件、この内訳の 2%カナダ: 引用元論文 154 件、この内訳の 1.8%日本: 引用元論文 154 件、この内訳の 1.8%
0%35.9%その他 24%

機関

分野

  • Medicine34.3%
  • Biochemistry, Genetics and Molecular Biology33.2%
  • Engineering6.9%
  • Immunology and Microbiology6.7%
  • Computer Science3.5%
  • Agricultural and Biological Sciences3.1%
  • その他12.3%

トピック

  • Cancer Immunotherapy and Biomarkers3.3%
  • Cancer-related molecular mechanisms research2.9%
  • MicroRNA in disease regulation2.8%
  • CAR-T cell therapy research2.3%
  • CRISPR and Genetic Engineering2%
  • Lung Cancer Treatments and Mutations2%
  • その他84.7%

共著者

全論文

検索で開く
  1. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

    著者: Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li, Yongsheng Wang - Signal Transduction and Targeted Therapy 2021 被引用: 932

  2. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

    著者: You Lü, Jianxin Xue, Tao Deng, Xiaojuan Zhou, Kun Yu, Lei Deng, Meijuan Huang, Xin Yi, Maozhi Liang, Yu Wang, Haige Shen, Ruizhan Tong, Wenbo Wang, Li Li, Jin Sook Song, Jing Li, Xiaoxing Su, Zhenyu Ding, Youling Gong, Jiang Zhu, Yongsheng Wang, Bingwen Zou, Yan Zhang, Yanying Li, Lin Zhou, Yongmei Liu, Min Yu, Yuqi Wang, Xuanwei Zhang, Limei Yin, Xuefeng Xia, Yong Zeng, Qiao Zhou, Binwu Ying, Chong Chen, Yuquan Wei, Weimin Li, Tony Mok - Nature Medicine 2020 被引用: 537

  3. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

    著者: Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou - The Lancet Respiratory Medicine 2020 被引用: 505

  4. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant

    著者: HARMONi-A Study Investigators, Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Fei Xu, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Lee Jia, Xu Shen, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Jun‐Guo Lu, Jifeng Feng, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, Weineng Feng, Wen Li, Jian‐An Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Zhang - JAMA 2024 被引用: 168

  5. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

    著者: Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Haibo Wang, Yongmei Yin, Xiaojia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shusen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yiding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yueyin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan - Nature Medicine 2024 被引用: 112

  6. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

    著者: Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, Shusen Wang, Noelia Martínez-Jáñez, Giuliano Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M. Fairhurst, Sabrina S. Khan, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli, for the TROPION-Breast01 Investigators, Betiana Romitelli, Ernesto Korbenfeld, Cristian Buono, Arturo Barbero, Geronimo Rosselli, Sergio Daniele, Sandra Anabel Ostoich, Hans Wildiers, Kevin Punie, Joëlle Collignon, Guy Jérusalem, Andrea Gombos, Giuliano Borges, Pedro Emanuel Rubini Liedke, Marcelle Goldner Cesca, Patrícia Medeiros Milhomem Beato, Laura Testa, Hélio Pinczowski, Liane Rapatoni, Debora de Melo Gagliato Jardim, José Bines, David W. Cescon, Jamil Asselah, Andre Blais, Joanne Yu, Jennifer Friedmann, Cristiano Ferrario, Binghe Xu, Shusen Wang, Qingyuan Zhang, ZeFei Jiang, Zhongsheng Tong, Quchang Ouyang, Jingfen Wang, Tingjing Yao, Yongsheng Wang, Xiaojia Wang, Meili Sun, Hui Li, Shu Wang, Yuan Sheng, Aimin Zang, Zhang Zhanmin, Wenyan Chen, Xian Wang, Zhong Ouyang, Wěi Li, Barbara Pistilli, Thomas Bachelot, Mony Ung, Cristian Villanueva, Delphine Garbay, Anne-Claire Hardy-Bessard, Audrey Mailliez, Stéphanie Bécourt, William Mina, Thomas Decker, Julia Radosa, Andreas Schneeweiß, Michael Braun, Bahriye Aktas, Gábor Rubovszky, Zsuzsanna Pápai, Tibor Csőszi, Yousuf Al-Farhat, Ankit Patel, Vineet Govinda Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sen Sharma, Rajani Priya Yedla, Michelino De Laurentiis, Ida Paris ほか 101 名 - Journal of Clinical Oncology 2024 被引用: 140

  7. Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy

    著者: Chuying Huang, Yishan Guo, Tuo Li, Guogen Sun, Jinru Yang, Yuqi Wang, Ying Xiang, Li Wang, Min Jin, Jiao Li, Yong Zhou, Bing Han, Rui Huang, Jiao Qiu, Yong Hui Tan, Jiaxing Hu, Yumiao Wei, Bo Wu, Yong Mao, Lingshan Lei, Xiusheng Song, Shuijie Li, Yongsheng Wang, Tao Zhang - Redox Biology 2024 被引用: 62

  8. Epithelium- and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response

    著者: Zunyong Feng, Jing Zhou, Yinhua Liu, Ruixue Xia, Qiang Li, Liang Yan, Qun Chen, Xiaobing Chen, Yuxin Jiang, Chao Gao, Ming Wang, Guoren Zhou, Yijie Zhang, Yongsheng Wang, Hongping Xia - Cell Death and Differentiation 2021 被引用: 92

  9. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

    著者: Zhimin Shao, Da Pang, Hongjian Yang, Wěi Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hweichung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Junjie Li, Julian Q. Zhou, Betsy Althaus, Yixiang Mao, Jennifer Eng‐Wong - JAMA Oncology 2019 被引用: 193

  10. Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression

    著者: Guifang Xu, Bin Zhang, Jiahui Ye, Shouli Cao, Jiajun Shi, Yan Zhao, Yongsheng Wang, Jianfeng Sang, Yongzhong Yao, Wenxian Guan, Jinqiu Tao, Min Feng, Weijie Zhang - International Journal of Biological Sciences 2019 被引用: 172

  11. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

    著者: Fei Ma, Min Yan, Wěi Li, Quchang Ouyang, Zhongsheng Tong, Yuee Teng, Yongsheng Wang, Shusen Wang, Cuizhi Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, Tao Sun, Qinguo Mo, Hu Liu, Ying Cheng, Jing Cheng, Xiaojia Wang, Jianyun Nie, Jin Yang, Xinhong Wu, Xinshuai Wang, Huiping Li, Changsheng Ye, Fangli Dong, Shu-chao Wu, Xiaoyu Zhu, Binghe Xu - BMJ 2023 被引用: 84

  12. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

    著者: Binghe Xu, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wěi Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Yongmei Yin, Yanxia Shi, Yueyin Pan, Yongsheng Wang, Weimin Xie, Min Yan, Yunjiang Liu, Ping Yan, Fei Wu, Xiaoyu Zhu, Jianjun Zou - Nature Medicine 2021 被引用: 169

  13. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

    著者: Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Xiang Lin, Jianjun Zou - BMC Medicine 2022 被引用: 82

  14. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

    著者: Dan Liu, Jun Zhou, Yongsheng Wang, Mingjun Li, Haiping Jiang, Yunpeng Liu, Xianli Yin, Minghua Ge, Xiaojun Xiang, Jieer Ying, Jian Huang, Yanqiao Zhang, Ying Cheng, Zhigang Huang, Xianglin Yuan, Weiqing Han, Dong Yan, Xinshuai Wang, Pan Liu, Linna Wang, Xiaojing Zhang, Suxia Luo, Tianshu Liu, Lin Shen - BMC Medicine 2022 被引用: 80

  15. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke

    著者: Dawei Chen, Yu Cui, Zhonghe Zhou, Ying-Jie Dai, Gaohua Li, Zhaolong Peng, Yi Zhang, Xiaodong Liu, Zhi-Mei Yuan, Changhao Jiang, Qingcheng Yang, Ying-Jie Duan, Guang-Bin Ma, Liwei Zhao, Ruixian Wang, Yuanlin Sun, Lei Shen, Er-Qiang Wang, Lihua Wang, Ye-Fang Feng, Fengyun Wang, Ren-Lin Zou, Heping Yang, Kai Wang, Duolao Wang, Yilong Wang, ARAIS Investigators, Xuewen Liu, Zilong Chen, Ming-Zhe Yu, Shuman Huang, Lian-Qiang Wang, Shi-Mei Geng, Shi-Huo Chen, Wei-Zhong Wang, Ming Zou, L X Hu, Dan Wang, Shiyong Zhang, Zai-Hui Zhang, Zhao Jiang, Liyun Wang, Sufang Wu, Run-Hui Li, Yongsheng Wang, Min Yu, Li Liu, Kui-Hua Yang, Hui Li, Haijun Wang, Jun-Hai Wang, Runxiu Zhu, Guoqiang Wen, Yongjun Cao, Qi-Da Zhou, Wenhai Yang - JAMA 2023 被引用: 65

  16. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial

    著者: Mengzhao Wang, Yun Fan, Meili Sun, Yongsheng Wang, Yanqiu Zhao, Bo Jin, Ying Hu, Zhigang Han, Xia Song, Anwen Liu, Kejing Tang, Cuimin Ding, Li Liang, Lin Wu, Junzhen Gao, Jianghong Wang, Ying Cheng, Jianying Zhou, Yong He, Xiaorong Dong, Yu Yao, Yan Yu, Huijie Wang, Si Sun, Jian‐An Huang, Jian Fang, Wen Li, Lin Wang, Xiubao Ren, Chengzhi Zhou, Yanping Hu, Dahai Zhao, Runxiang Yang, Fei Xu, Yijiang Huang, Yueyin Pan, Jiuwei Cui, Yan Xu, Zhenfan Yang, Yuankai Shi - The Lancet Respiratory Medicine 2023 被引用: 66

  17. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

    著者: Qizhi Ma, Xia He, Benxia Zhang, Fuchun Guo, Xuejin Ou, Qiyu Yang, Pei Shu, Yue Chen, Kai Li, Ge Gao, Yajuan Zhu, Diyuan Qin, Jie Tang, Xiaoyu Li, Jing Meng, Jian Zhao, Zeming Mo, Ning Liu, Yao Zeng, Kexun Zhou, Mingyang Feng, Wei‐Ting Liao, Wanting Lei, Qiu Li, Dan Li, Yongsheng Wang - Signal Transduction and Targeted Therapy 2022 被引用: 48

  18. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer

    著者: Yang Shu, Weihan Zhang, Qianqian Hou, Lin-Yong Zhao, Shouyue Zhang, Jiankang Zhou, Xiao-Hai Song, Yan Zhang, Dan Jiang, Xin‐Zu Chen, Peiqi Wang, Xuyang Xia, Fei Liao, Dandan Yin, Xiao‐Long Chen, Xueyan Zhou, Duyu Zhang, Senlin Yin, Kun Yang, Jianping Liu, Leilei Fu, Lan Zhang, Yuelan Wang, Jun‐Long Zhang, Yunfei An, Hua Cheng, Bin Zheng, Hongye Sun, Yinglan Zhao, Yongsheng Wang, Dan Xie, Liang Ouyang, Ping Wang, Yaoguang Zhang, Meng Qiu, Xianghui Fu, Lunzhi Dai, Gu He, Hanshuo Yang, Wei Cheng, Li Yang, Bo Liu, Weimin Li, Biao Dong, Zong‐Guang Zhou, Yuquan Wei, Yong Peng, Heng Xu, Jian‐Kun Hu - Nature Communications 2018 被引用: 143

  19. Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

    著者: Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Yanfei Tai, Xinjing Ma, Wei Shi - Journal of Thoracic Oncology 2023 被引用: 69

  20. Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer libraries

    著者: Yu-Xi Tsai, Ning-En Chang, Klaus Reuter, Hao‐Ting Chang, Tzu‐Jing Yang, Sören von Bülow, Vidhi Sehrawat, Noémie Zerrouki, Matthieu Tuffery, Michael Gecht, Isabell Louise Grothaus, Lucio Colombi Ciacchi, Yongsheng Wang, Min‐Feng Hsu, Kay‐Hooi Khoo, Gerhard Hummer, Shang‐Te Danny Hsu, Cyril Hanus, Mateusz Sikora - Cell 2024 被引用: 65

  21. Preclinical Evaluation of Chimeric Antigen Receptor–Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer

    著者: Binglan Zhang, Dan Li, Youling Gong, Yong Huang, Diyuan Qin, Lin Jiang, Xiao Liang, Xiao Yang, Hongfeng Gou, Yongsheng Wang, Yu-Quan Wei, Wei Wang - Human Gene Therapy 2019 被引用: 89

  22. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis

    著者: Na Li, Zhongping Gou, Shuangqing Du, Xiaohong Zhu, Hui Lin, Xiufang Liang, Yongsheng Wang, Ping Feng - Clinical Rheumatology 2022 被引用: 63

  23. Anti‐tumour strategies aiming to target tumour‐associated macrophages

    著者: Xiaoqiang Tang, Chunfen Mo, Yongsheng Wang, Dandan Wei, Hengyi Xiao - Immunology 2012 被引用: 291

  24. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors

    著者: Binglan Zhang, Diyuan Qin, Zeming Mo, Yi Li, Wei Wei, Yongsheng Wang, Wei Wang, Yu-Quan Wei - Science China Life Sciences 2016 被引用: 102